Slide 1: Corporate Presentation
CORPORATE PRESENTATION
Slide 2: Disclaimer
DISCLAIMER CONFIDENTIALITY This Document has been drafted by Cube Labs S.p.A. (hereinafter the "Company") solely for the purpose of this presentation. The Document may not be reproduced or distributed, in whole or in part, by any person other than the Company. The Company assumes no responsibility f
Slide 3: Founders
FOUNDERS Renato Del Grosso Massimo Fiocchi Filippo Surace Co-Founder & Co-Founder & Founder & CEO Chief Strategy Officer Chief Financial Officer EDUCATION AND TRAINING EDUCATION AND TRAINING EDUCATION AND TRAINING KEY PROFESSIONAL EXPERIENCE KEY PROFESSIONAL EXPERIENCE KEY PROFESSIONAL EXPERIENCE 3
Slide 4: Index
INDEX 1 COMPANY OVERVIEW p. 5 2 BUSINESS MODEL p. 13 3 SPIN-OFF PORTFOLIO p. 18 4 IPO p. 24 5 FINANCIAL RESULTS p. 29 6 CAPITAL INCREASE p. 32 7 ESG IMPACT p. 34 8 APPENDIX: TEAM AND p. 37 STRATEGIC ADVISORY BOARD
Slide 5: Company Overview
COMPANY 1 OVERVIEW
Slide 6: Cube Labs at a Glance
CUBE LABS AT A GLANCE Cube Labs S.p.A. is an Italian Venture Builder specialized in the development of projects in the healthcare technologies sector. Cube Labs has been listed since March 21, 2023 on Euronext Growth Milan - Professional segment, dedicated to SMEs with high growth potential. 3 offic
Slide 7: Our Figures
OUR FIGURES 18 11 24 54.4M€ Exclusive Spin-offs1 licenses Universities in INBB Assets network2 value4 60 700 88 Researchers in INBB network2 patents Research centers in CNR network3 1. Including one newly established spin-off, ChromaPatch. 2. www.inbb.it/chi-siamo/universita-aderenti. 3. www.cnr.it/
Slide 8: Governance and Shareholding
GOVERNANCE AND SHAREHOLDING BOARD OF DIRECTORS Filippo Surace Chairman and CEO Renato Del Grosso Massimo Fiocchi Member of Board Member of Board Domenico Colella Giuseppina Staropoli Non-executive Director Independent Director AUDITING FIRM F. Surace* Free Float** ** of which 8.01% is held by 63.37%
Slide 9: Development Strategy
DEVELOPMENT STRATEGY SHORT TERM STRATEGY MID-LONG TERM STRATEGY VALORIZATION OF THE SUBSIDIARY R&D ACTIVITIES ON ADDITIONAL INITIATIVES COMPANIES BY INCREASING R&D ACTIVITY ON ALREADY IN THE PORTFOLIO SELECTED INITIATIVES CORPORATE FINANCE & Cube Labs intends to increase its R&D activity in COMMERCI
Slide 10: Our Story
OUR STORY 2013 Cube Labs Incorporation 2014 - 2016 • Pilot program and scientific networking; • Blue ocean expansion in China, Spain and CEE. • 10 new portfolio companies in partnership with I.N.B.B.; 2017 - 2020 • Expansion in Switzerland and Israel; • Seed investment by CDP VC SGR in 4 spin-offs.
Slide 11: Global Footprint
GLOBAL FOOTPRINT Italy France Poland Spain Germany Italy USA Israel India 11
Slide 12: Accelerating ESG Impact
ACCELERATING ESG IMPACT DEMOCRATIZATION ACCESSIBILITY A HEALTHIER FUTURE Pervasive knowledge as a Life Sciences accessible to all. Our ESG approach for a healthier widespread economic advantage. Our vision, our tangible future. Promoting innovation The technology transfer through commitment. and sup
Slide 13: Business Model
BUSINESS 2 MODEL
Slide 14: Our Venture Building Approach
OUR VENTURE BUILDING APPROACH Cube Labs builds new companies from promising R&D activities, transforming pioneering science into real-world healthcare solutions. As a venture builder, it supports selected projects from their earliest stages: BUILDING FINANCING GROWTH We provide We source proprietary
Slide 15: Business Model
BUSINESS MODEL Cube Labs is a shareholder of subsidiaries that hold academic research projects that have passed the Proof of Concept (PoC), and that come mainly from the partnership with INBB. The Company selects academic projects with high development potential. A key point of Cube Labs’ business m
Slide 16: Key Success Factors
KEY SUCCESS FACTORS FIRST MOVER SUCCESSFUL TEAM HIGH DEGREE OF CONTROL Experts with international Cube Labs is the first venture experience in both industry- From the initial stages builder in healthcare sector, leading companies and to the commercialization listed on EGM – Professional top academic
Slide 17: Revenue Model
REVENUE MODEL Innovative revenues model with streamline from spin-offs to the Holding enabling Cube Labs to be independent from continuous capital injections in order to improve its spin-offs portfolio up to the exits. E.G. co-working spaces, international desks, Service Fee facilities, advisory, me
Slide 18: Portfolio
OMM0OsALYOd AAO-NIdS
Slide 19: Our Focus Areas
OUR FOCUS AREAS PHARMACEUTICALS BIOTECH NUTRACEUTICALS Synthesis phase of active Preclinical or phase 1 Between TRL 3 substance achieved or clinical clinical phase. and TRL 7. validation achieved. R&D TECH/AI MEDTECH Artificial Intelligence applied Between TRL 3 to bio-health sector. and TRL 7. 19
Slide 20: Spin-off Portfolio
SPIN-OFF PORTFOLIO PHARMACEUTICALS PHARMACEUTICALS PHARMACEUTICALS Regenerative Solutions for the technologies against treatment of rare Development of natural osteoarthritis and diseases, which occur and synthetic molecules related diseases. They rarely and for which for diabetes, obesity developed
Slide 21: Spin-off Portfolio
SPIN-OFF PORTFOLIO NUTRACEUTICALS BIOTECH R&D TECH/AI Pioneering dual- Myrtoviva aims to component technology innovate the field of combining a food supplements and biocompatible carrier Development of cosmetic products by and microbiome-based Artificial Intelligence the combination of formulation t
Slide 22: Spin-off Portfolio
SPIN-OFF PORTFOLIO MEDTECH MEDTECH MEDTECH Biocompatible, Advanced technologies biodegradable, and in for detecting micro- and situ cross-linkable nanoplastics. Using hydrogels that adhere Development of bio- electronic devices with to both soft and hard sensors for diagnostic, fluorogenic probes, i
Slide 23: Full Asset Valuation: Overview
FULL ASSET VALUATION: OVERVIEW This overview facilitates direct comparison, highlighting the increased portfolio value (M€) due to recent developments. RANGE Low Mean High 20% First line represents the portfolio value in 2021 discount rate 62.2 84.3 113.7 2022* with a discount rate of 20%. 20% Secon
Slide 24: IPO
IPO 4
Slide 25: Listing IPO EGM Pro
LISTING IPO EGM PRO Number of shares pre-IPO 15,000,000 Shares newly issued 5,035,850 Warrant after conversion (18/10/2024) 1,752,500 Number of outstanding shares 20,035,850 Free Float 25.47%* IPO Date March 21, 2023 Issue Price (€) 2.00 Market Cap (€/M) @ IPO 34,105 EGM Market EGM PRO Title update
Slide 26: EGM Pro Performance
EGM PRO PERFORMANCE Total volume Average volume 2024 Total volume 2024 Average volume 2025 Total volume 2025 2024+2025 28.8 K 1.04 M 1.2 M 13.1 K 210 K * Counting only the days when shares were traded. As of 26 August 2025. Source: Yahoo Finance API. 26
Slide 27: EGM Pro Benchmark
EGM PRO BENCHMARK NAME SYMBOL INDUSTRY YEAR MARKET CAP MTD. PERF. YoY PERF. BOLOGNAFIERE BF Consumer Discretionary 2023 € 243,514,321 0.0% 0.0% E-NOVIA E9IA Financials 2022 € 55,362,402 0.0% -51.7% CUBE LABS CUBE Financials 2023 € 46,495,323 1.7% 8.2% HOMIZY HZY Consumer Discretionary 2021 € 42,654,
Slide 28: Company Portfolio Value Breakdown
COMPANY PORTFOLIO VALUE BREAKDOWN Intermonte, independent corporate broker, identifies significant growth potential for the company. NAV Reflecting a 12-month outlook, 2025 NAV is projected to be double the current market price. In future years, while various project milestones are achieved, the pot
Slide 29: Financial Results
SLINSAY TIWIDSNVNISA
Slide 30: Balance Sheet
BALANCE SHEET Balance sheet (€/000) FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 H1 2025 Intangible asset 10 9 15 344 1,161 1,039 0,874 Tangible asset 2 2 3 2 1 6 8 Financial asset 349 51,744 52,108 52,312 53,104 53,736 54,435 Assets 361 51,755 52,126 52,657 54,266 54,781 55,318 Other non-current
Slide 31: Income Statement
INCOME STATEMENT Income statement (€/000) FY 2020 FY 2021 FY 2022 FY2023 FY 2024 Income statement (€/000) H1 2024 H1 2025 Value of production 950 1,127 1,143 1,637 2,108 Value of production 982 1,372 Var YoY% +67.3% +18.6% +1.42% +43.2% +28,8% Var YoY% +39,8% Raw materials (2) (5) (3) (3) (5) Raw ma
Slide 32: Capital Increase
CAPITAL 6 INCREASE
Slide 33: Capital Increase
CAPITAL INCREASE € 5,000,000.00 € 10,000,000.00 € 5,000,000.00 The shareholders' meeting of Cube Labs S.p.A. The Assembly has also approved the delegation has approved a capital increase of up to to the Board of Directors to increase the share €5,000,000.00, inclusive of any share premium. capital,
Slide 34: ESG Impact
tovdwiosa /.
Slide 35: Democratization of Life Sciences: The A's
DEMOCRATIZATION OF LIFE SCIENCES: THE 5 A's A ffordability The extent to which a patient’s financial ability matches the cost of the service and/or care. Availability The availability of necessary resources such as personnel, technology, and care to meet the patient's needs. Accessibility How easily
Slide 36: Democratization: The Venture Builder's Role
DEMOCRATIZATION: THE VENTURE BUILDER'S ROLE COST CONTAINMENT BRIDGING STRATEGIES ETHICAL THE GAP Reducing healthcare costs through investments in FUNDING BETWEEN SCIENCE SOURCES preventive care, digital AND MARKET health technologies, Partnering with Advancing scientific and personalized investors w
Slide 37: Appendix: Team and SAB
APPENDIX: 8 TEAM AND SAB
Slide 38: Board of Directors
BOARD OF DIRECTORS Filippo Surace Renato Del Grosso Massimo Fiocchi Chairman & CEO Chief Strategy Officer Chief Financial Officer • Serial entrepreneur and innovator with 30+ years of • 17+ years’ experience in market access and • Certified accountant with extensive experience experience in the medi
Slide 39: Executive Leadership
EXECUTIVE LEADERSHIP Neil Thomas Chris Hentschel Natalie Pankova Chief Business Officer Chief Scientific Officer Chief Operating Officer • Partner in Ventac Partners since 2012 with • Molecular biologist and Co-founder of The Ulysses executive roles in their portfolio companies. Advisory Group. • Do
Slide 40: Executive Management
EXECUTIVE MANAGEMENT Daria Brambilla Giorgia Bellantonio Fabio Scognamiglio Scientific Head of Head of People Vice-President, Finance Venture Companies and Culture • Global HR leader with experience in driving • Consolidated experience in biochemistry, sustainable business performance, creating • Te
Slide 41: Strategic Advisory Board
STRATEGIC ADVISORY BOARD Yossi Bornstein Adam Broncel Slawomyr Chomik • Over 35 years in Israeli & International biomed industry • Co-founder and former GP, Biomed Venture Capital Fund • CEO and Founder of Shizim Group, ShizimXL (medical • Founder of Poland Ventures • Over 20 years experience in the
Slide 42: Strategic Advisory Board
STRATEGIC ADVISORY BOARD Pierre A. Morgon Mikael Oerum Fintan Walton • CEO of MRGN Advisors • 40 years of experience in the pharmaceutical, • Regional Partner for Switzerland at Mérieux Equity • CEO and Founder, PharmaVentures, a premier transaction advisory biotech and finance sectors firm Partners
Slide 43: Get in Touch!
GET IN TOUCH! Cube Labs S.p.A. Via G. Caccini, 1 00198 – Rome, Italy www.cube-labs.com info@cube-labs.com